Severe Ketoacidosis Associated with Canagliflozin (Invokana): A Safety Concern
Joint Authors
Haidar, Abdallah
Gelaye, Alehegn
Kassab, Christina
Kazmi, Syed
Sinha, Prabhat
Source
Issue
Vol. 2016, Issue 2016 (31 Dec. 2016), pp.1-3, 3 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2016-03-21
Country of Publication
Egypt
No. of Pages
3
Main Subjects
Abstract EN
Canagliflozin (Invokana) is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor that was first introduced in 2013 for the treatment of type 2 diabetes mellitus (DM).
Though not FDA approved yet, its use in type 1 DM has been justified by the fact that its mechanism of action is independent of insulin secretion or action.
However, some serious side effects, including severe anion gap metabolic acidosis and euglycemic diabetic ketoacidosis (DKA), have been reported.
Prompt identification of the causal association and initiation of appropriate therapy should be instituted for this life threatening condition.
American Psychological Association (APA)
Gelaye, Alehegn& Haidar, Abdallah& Kassab, Christina& Kazmi, Syed& Sinha, Prabhat. 2016. Severe Ketoacidosis Associated with Canagliflozin (Invokana): A Safety Concern. Case Reports in Critical Care،Vol. 2016, no. 2016, pp.1-3.
https://search.emarefa.net/detail/BIM-1100422
Modern Language Association (MLA)
Gelaye, Alehegn…[et al.]. Severe Ketoacidosis Associated with Canagliflozin (Invokana): A Safety Concern. Case Reports in Critical Care No. 2016 (2016), pp.1-3.
https://search.emarefa.net/detail/BIM-1100422
American Medical Association (AMA)
Gelaye, Alehegn& Haidar, Abdallah& Kassab, Christina& Kazmi, Syed& Sinha, Prabhat. Severe Ketoacidosis Associated with Canagliflozin (Invokana): A Safety Concern. Case Reports in Critical Care. 2016. Vol. 2016, no. 2016, pp.1-3.
https://search.emarefa.net/detail/BIM-1100422
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1100422